Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.

19 Jun 2012

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

Innate Immunotherapeutics today announced positive interim data from the company's Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).

18 Jun 2012

movin' mania, a community wide effort to address childhood obesity

Bon Secours Virginia Health System has launched movin' mania, a community wide effort to address childhood obesity, the leading health concern for children today. The health system gathered community partners and hundreds of area school children for a kickoff rally Thursday at the Science Museum of Virginia.

18 Jun 2012

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed.

18 Jun 2012

Concord Medical acquires 52% equity ownership in Chang'an Hospital

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has closed the acquisition of 52% equity ownership in Chang'an Hospital, a leading non-public general hospital located in Xi'an, Shaanxi Province.

18 Jun 2012

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

18 Jun 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

Agility MLC's new design provides better dose sculpting capabilities

Requiring only a quick upgrade to their existing Elekta Synergy linear accelerator, physicians at SALK and Paracelsus Medical University began using the new Agility 160-leaf multileaf collimator (MLC), treating 33 patients on its first day. In its first month of Agility use, the center now treats 50 patients per day, comprising about 700 individual treatment sessions that have benefited from this breakthrough in cancer care.

From Elekta 18 Jun 2012

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

NHS Supply Chain will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy radiation therapy treatment systems.

From Elekta 18 Jun 2012

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

Tobacco cessation must be included as part of standard clinical care for cancer patients

While tobacco use can significantly hamper cancer treatment, few cancer researchers are incorporating tobacco assessment into their clinical studies. That's the conclusion a group of investigators led by Graham Warren, MD, PhD, Assistant Professor in the Department of Radiation Medicine at Roswell Park Cancer Institute (RPCI), drew from a recent survey of cancer clinical trials.

16 Jun 2012

Stereotactic ablative radiotherapy benefits stage I non-small cell lung cancer patients

Until recently, many elderly patients with stage I non-small cell lung cancer were left untreated because treatment may not improve their quality of life. However, stereotactic ablative radiotherapy (SABR) has become one of the standards of treatment for these patients. The outpatient treatment given over a two-week period allows frail patients to undergo the treatment.

16 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Surgeon specialty, hospital volume important factors in patient outcomes

In other studies, outcomes of specific surgeries has been shown to improve when performed at high-volume centralized centers. Researchers from the Netherlands Cancer Institute wanted to understand if patients undergoing lung cancer resections would benefit from having their procedures performed in a high-volume specialized center.

16 Jun 2012

HCA, HealthONE expand Colorado Center for Robotic Surgery

People who may be considering surgery for a disease or medical condition now have greater access to the most advanced type of minimally invasive procedures available in Colorado. Cherry Creek Shopping Center visitors will be able to "test drive" the new da Vinci Robots in a one-of-a-kind experience on June 18 in the Center's Grand Court.

16 Jun 2012

Researchers identify three sets of genetic markers linked with CNS PNET

Researchers at The University of Nottingham have identified three sets of genetic markers that could potentially pave the way for new diagnostic tools for a deadly type of brain tumour that mainly targets children.

16 Jun 2012

Oncology News and Research

Further Reading

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

movin' mania, a community wide effort to address childhood obesity

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Concord Medical acquires 52% equity ownership in Chang'an Hospital

Ambrx, Merck collaborate to develop and commercialize biotherapeutic drug conjugates

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Agility MLC's new design provides better dose sculpting capabilities

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Tobacco cessation must be included as part of standard clinical care for cancer patients

Stereotactic ablative radiotherapy benefits stage I non-small cell lung cancer patients

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Surgeon specialty, hospital volume important factors in patient outcomes

HCA, HealthONE expand Colorado Center for Robotic Surgery

Researchers identify three sets of genetic markers linked with CNS PNET

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News